Mumbai
Tier 1
$2,200 - $8,500 per cycle
Premium hospitals and imported drugs can lift per-cycle pricing.
Immunotherapy cost
Immunotherapy cost in India by drug, biomarker, and city
Plan immunotherapy with USD ranges for checkpoint inhibitors, biomarker testing, cycle schedules, toxicity monitoring, and oncology hospital selection across India.
How much does immunotherapy cost in India?
Immunotherapy in India commonly ranges from about $1,500 to $8,500 per cycle depending on the drug, dose, cancer type, biomarker status, cycle interval, hospital city, and monitoring needs. The total cost depends on how many cycles are planned and whether immune-related side effects require steroids, specialist review, or admission.
City-wise cost
USD range by Indian city
These ranges are planning bands. A hospital-backed quote should be requested after reports, diagnosis, and fitness details are reviewed.
City Tier USD range Planning note
Delhi NCR
Tier 1
$2,100 - $8,300 per cycle
Useful for biomarker review and complex immunotherapy decisions.
Gurugram
Tier 1
$2,200 - $8,500 per cycle
Often chosen for advanced oncology monitoring and international coordination.
Bangalore
Tier 1
$2,000 - $8,000 per cycle
Strong for molecular review and multi-specialty toxicity support.
Chennai
Tier 1
$1,900 - $7,800 per cycle
Established oncology market for checkpoint-inhibitor protocols.
Hyderabad
Tier 1
$1,850 - $7,600 per cycle
Can provide efficient infusion planning when drug choice is clear.
Pune
Major metro
$1,750 - $7,000 per cycle
Useful for stable infusion cycles after specialist approval.
Ahmedabad
Major metro
$1,700 - $6,800 per cycle
Competitive when biomarker reports and protocol are ready.
Kolkata
Major metro
$1,650 - $6,600 per cycle
Can work for repeated cycles with clear monitoring.
Indore
Tier 2
$1,500 - $5,900 per cycle
Consider for stable cycles only after confirming toxicity-response support.
Bhopal
Tier 2
$1,500 - $5,800 per cycle
Lower local stay cost can help during repeated maintenance cycles.
Vizag
Tier 2
$1,600 - $6,100 per cycle
Confirm drug availability, oncologist supervision, and emergency care.
Tier choice
When Tier 1 or Tier 2 cities may make sense
Tier 1 for new or complex starts
First cycles, combination therapy, lung toxicity risk, or uncertain eligibility often fit Tier 1 centers better.
Tier 2 for stable ongoing cycles
Maintenance cycles may be possible in selected Tier 2 cities if the drug and emergency plan are reliable.
Plan for side effects
Immune toxicity can involve multiple organs, so hospital backup matters even when the infusion seems simple.
Included
What the estimate usually covers
Immunotherapy drug
Named checkpoint inhibitor or immunotherapy medicine for the quoted cycle.
Drug name and dose are essential.
Infusion setup
Day-care infusion, nursing, routine monitoring, and standard pre-infusion checks.
Cycle interval should be clear.
Oncologist review
Medical oncology assessment before treatment continuation.
Response and toxicity guide cycles.
Basic labs
Selected blood tests may be bundled depending on hospital policy.
Thyroid, liver, kidney, and sugar checks matter.
Not included
What patients should confirm separately
Biomarker testing
PD-L1, MSI, MMR, TMB, NGS, or repeat pathology testing if not included.
Eligibility often depends on these.
Immune toxicity care
Steroids, endocrinology, pulmonology, gastroenterology, ICU, or admission for side effects.
Can occur even after earlier cycles.
Response scans
PET CT, CT, MRI, or tumor markers used to check effect.
Usually separate from drug cycle cost.
Long-term cycles
Maintenance cycles over months can multiply total cost.
Ask expected duration.
Cost drivers
Factors that can change the final estimate
Drug and dose
Different immunotherapy medicines and weight-based dosing can change cycle price.
Always compare drug names.
Biomarker status
PD-L1, MSI, MMR, TMB, and mutation results can affect eligibility and sequencing.
Testing can prevent unsuitable cost.
Cycle schedule
Two-week, three-week, four-week, or six-week schedules create different total costs.
Cycle interval matters.
Combination therapy
Immunotherapy plus chemo or targeted therapy can increase cost and side-effect risk.
Ask whether it is combined.
Side-effect monitoring
Immune effects can involve lung, liver, bowel, thyroid, skin, or hormone glands.
Hospital support matters.
Reports
Reports needed for a more accurate quote
The report checklist is different for each treatment so every cost page avoids generic duplicated content.
Immunotherapy reports
Eligibility and safety depend on cancer type, biomarkers, and prior treatment.
Pathology and cancer type
Confirms whether immunotherapy is relevant for the diagnosis.
PD-L1, MSI, MMR, or NGS
Biomarkers can support or limit immunotherapy use depending on cancer type.
Prior treatment history
Previous chemotherapy, targeted therapy, radiation, or immunotherapy affects sequencing.
Autoimmune and organ history
Autoimmune disease, lung inflammation, liver disease, thyroid issues, or steroid use can affect safety.
Hospital selection
How to compare hospitals beyond the lowest package
Drug transparency
Confirm drug name, dose, brand, schedule, and whether the vial cost is fully included.
Avoid vague quotes.
Biomarker process
Ask how PD-L1, MSI, MMR, or NGS reports are reviewed before treatment.
Eligibility matters.
Toxicity response
Confirm access to pulmonology, gastroenterology, endocrinology, ICU, and steroid protocols.
Immune side effects can be serious.
Response tracking
Ask when scans are planned and how pseudo-progression or mixed response is handled.
Specialist review is needed.
Patient journey
From first estimate to treatment travel
Eligibility review
Cancer type, stage, biomarkers, prior therapy, and patient fitness are reviewed.
Drug and cycle plan
The oncologist confirms drug name, dose, interval, expected duration, and response checkpoints.
Infusion city selection
The patient compares drug availability, monitoring support, and total stay cost.
Toxicity and response follow-up
Side effects and scans decide whether treatment continues, pauses, or changes.
Recovery planning
Stay, follow-up, and return-home planning
Between-cycle monitoring
Patients should track breathlessness, diarrhea, rash, fever, fatigue, jaundice, and hormone symptoms.
Scan checkpoints
Response scans should be scheduled before deciding whether to continue expensive cycles.
Home coordination
Local doctors should receive drug names, dates, side effects, and steroid instructions.
Questions
Common questions
Why is immunotherapy so expensive?
The drug itself is costly, and the total depends on dose, brand, cycle interval, number of cycles, biomarker testing, and monitoring.
Is immunotherapy suitable for every cancer patient?
No. Suitability depends on cancer type, stage, biomarkers, prior treatment, overall health, and specialist judgment.
Can immunotherapy be done in Tier 2 cities?
Stable ongoing cycles may be possible in selected Tier 2 cities, but first cycles or complex cases should have stronger oncology backup.
What reports are needed for an immunotherapy quote?
Pathology, stage, PD-L1 or other biomarker reports, prior treatments, scans, blood tests, and autoimmune history are useful.
Does the estimate include biomarker testing?
Not always. PD-L1, MSI, MMR, TMB, or NGS testing should be listed separately if needed.
Can immunotherapy side effects appear late?
Yes. Immune-related side effects can occur during treatment or after cycles, so patients need clear warning signs and emergency contacts.
How many cycles are needed?
It depends on cancer type, response, tolerance, protocol, and oncologist advice. Patients should ask for expected duration before budgeting.
Can Virello compare immunotherapy estimates?
Yes. Virello can compare drug names, dose, cycle interval, biomarker logic, monitoring, city fit, and total planning cost.